Author: Chauhan, Gaurav; Madou, Marc J.; Kalra, Sourav; Chopra, Vianni; Ghosh, Deepa; Martinez-Chapa, Sergio O.
Title: Nanotechnology for COVID-19: Therapeutics and Vaccine Research Cord-id: 85zogvak Document date: 2020_6_22
ID: 85zogvak
Snippet: [Image: see text] The current global health threat by the novel coronavirus disease 2019 (COVID-19) requires an urgent deployment of advanced therapeutic options available. The role of nanotechnology is highly relevant to counter this “virus†nano enemy. Nano intervention is discussed in terms of designing effective nanocarriers to counter the conventional limitations of antiviral and biological therapeutics. This strategy directs the safe and effective delivery of available therapeutic opti
Document: [Image: see text] The current global health threat by the novel coronavirus disease 2019 (COVID-19) requires an urgent deployment of advanced therapeutic options available. The role of nanotechnology is highly relevant to counter this “virus†nano enemy. Nano intervention is discussed in terms of designing effective nanocarriers to counter the conventional limitations of antiviral and biological therapeutics. This strategy directs the safe and effective delivery of available therapeutic options using engineered nanocarriers, blocking the initial interactions of viral spike glycoprotein with host cell surface receptors, and disruption of virion construction. Controlling and eliminating the spread and reoccurrence of this pandemic demands a safe and effective vaccine strategy. Nanocarriers have potential to design risk-free and effective immunization strategies for severe acute respiratory syndrome coronavirus 2 vaccine candidates such as protein constructs and nucleic acids. We discuss recent as well as ongoing nanotechnology-based therapeutic and prophylactic strategies to fight against this pandemic, outlining the key areas for nanoscientists to step in.
Search related documents:
Co phrase search for related documents- acute respiratory syndrome and adaptive immune response specific: 1, 2, 3, 4
- acute respiratory syndrome and adaptive target: 1
- acute respiratory syndrome and ade antibody dependent enhancement: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31
- acute respiratory syndrome and adhesion molecule: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30
- acute respiratory syndrome and adjuvant antigen: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- acute respiratory syndrome and adjuvant nanoparticle: 1
- acute respiratory syndrome and adjuvant strategy: 1, 2, 3
- acute respiratory syndrome and liver bypass: 1
- acute respiratory syndrome and liver pancreas: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
- acute respiratory syndrome and liver targeting: 1
- acute respiratory syndrome and load nanoparticle: 1
- acute respiratory syndrome and loaded antigen: 1, 2
- acute respiratory syndrome and loop helix: 1, 2, 3
- acute respiratory syndrome and loop region: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- acute respiratory syndrome and low bioavailability: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- acute respiratory syndrome and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- acute respiratory syndrome and lung tissue virus infection: 1
- acute respiratory syndrome and lymph node: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35
- acute respiratory syndrome and macrophage dependent: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date